Traphaco has appointed Ms. Dao Thuy Ha as the new CEO for the 2021-2026 term, succeeding Mr. Tran Tuc Ma, who stepped down due to personal reasons. The decision takes effect from November 10th.
Ms. Dao Thuy Ha, born in 1975, holds a Master’s degree in Pharmacy and a Master’s in Business Administration. She joined Traphaco in 1996 and has nearly three decades of experience across market planning, R&D, and new product development. Prior to her appointment as CEO, she served as Deputy CEO overseeing Sales and Marketing, while also being a Board Member and representing 11.55% of SCIC’s capital in TRA. She personally owns 0.18% of the company’s equity.
Ms. Ha is considered a key figure in implementing Traphaco’s “dual development strategy,” focusing on both traditional and modern pharmaceuticals, alongside international technology transfer and digital transformation.
Mr. Tran Tuc Ma and Ms. Dao Thuy Ha – Traphaco’s new CEO
|
Her predecessor, Mr. Tran Tuc Ma, born in 1965, served as CEO from March 2011, totaling over 15 years in the role. He joined Traphaco in 1994 and has been with the company for over three decades, holding positions such as Sales Manager, Head of the Supervisory Board, and Board Member. Despite stepping down from executive duties, he remains a Board Member and holds over 1.7 million TRA shares, equivalent to 4.16% of the company’s capital.
Traphaco also received the resignation of Ms. Nguyen Thi Giang from the Supervisory Board on November 4th, which will be submitted to the General Meeting of Shareholders for approval at the next session.
In Q3/2025, Traphaco reported a net profit of over VND 68 billion, up 78% year-on-year. For the first nine months, the company achieved nearly VND 179 billion in net profit, a 12% increase, and VND 1,936 billion in revenue, up 12%, marking the highest nine-month revenue in its history. The company has fulfilled 76% of its annual revenue target and 75% of its post-tax profit goal. Growth was driven by increased sales of core products and expanded OTC channel coverage.
| Traphaco’s Nine-Month Business Results Over the Years |
On the HOSE market, TRA shares rose nearly 2% in the morning session of November 10th to VND 67,500 per share, though they remain down nearly 8% over the past year. Average liquidity remains below 65,000 shares per day.
| TRA Share Price Movement Over the Past Year |
– 10:38 10/11/2025
Peace Corporation Sitting on Hundreds of Billions in Cash, Yet Still Delaying Debt Payments
As of September 30, Hòa Bình Construction Group held over 319 billion VND in cash. However, by October 31, the company defaulted on a principal payment of more than 12 billion VND for its HBCH2225002 bond issuance, citing inability to secure sufficient funds as the reason.
An Binh Securities Appoints New CEO
An Binh Securities has appointed Mr. Nguyen Quang Dat as its Chief Executive Officer for a two-year term, effective November 1, 2025.
IMEXPHARM’s Gross Revenue Surges 21% to VND 2,118 Billion in First Nine Months of 2025
On October 20, 2025, Imexpharm announced its business results for the first nine months of 2025, reporting net revenue of VND 1,800 billion, a 16% increase compared to the same period last year, with EBITDA margin rising to 22.3%.
Pharmaceutical Marketing: A Unique Perspective from DHG Pharma’s Chief Marketing Officer
Nguyễn Ngọc Toàn is not only the driving force behind DHG Pharma’s leading antibiotic division, which accounts for the largest revenue share of this top Vietnamese pharmaceutical company, but he is also fondly remembered by hospital doctors and pharmacists for his sincerity, passion, and compassion.
DHG Pharma Maintains 14-Year Streak in Vietnam’s Top 50 Most Efficient Business Companies
On September 27, 2025, at the Corporate Governance Conference 2025 held in Ho Chi Minh City, DHG Pharma was once again honored as one of the 50 Most Effective Business Companies in Vietnam 2025. This marks the 14th consecutive year the company has been among the top 5 recipients of this prestigious recognition, solidifying its position as the leading domestic pharmaceutical company in the nation.
